<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Several receptor tyrosine kinases (TKs) are involved in the pathogenesis of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we have assessed the expression of the Recepteur d'Origine Nantais (RON) in leukemic cell lines and samples from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>In a series of 86 AML patients, we show that both the full length and/or the short form (sf) of RON are expressed in 51% and 43% of cases, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Interestingly, sfRON is not expressed in <z:mpath ids='MPATH_458'>normal</z:mpath> CD34+ hematopoietic cells and induces part of its oncogenic signaling through interaction with the Src kinase Lyn </plain></SENT>
<SENT sid="4" pm="."><plain>sfRON-mediated signaling in leukemic cells also involves mTORC1, the proapoptotic bcl2-family member, BAD, but not the phosphatidylinositol 3-kinase/Akt pathway </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, the expression of sfRON was specifically downregulated by <z:chebi fb="0" ids="2038">5-azacytidine</z:chebi> (AZA) </plain></SENT>
<SENT sid="6" pm="."><plain>Conversely, AZA could induce the expression of sfRON in sfRON-negative leukemic cells suggesting that the activity of this drug in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> could involve modulation of TKs </plain></SENT>
<SENT sid="7" pm="."><plain>cMET/RON inhibitors exhibited an antileukemic activity exclusively in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> samples and cell lines expressing sfRON </plain></SENT>
<SENT sid="8" pm="."><plain>These results might support clinical trials evaluating cMET/RON inhibitors in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients expressing sfRON </plain></SENT>
</text></document>